written on 11.03.2014
Tags:
,

Nexavar flunks PhIII adjuvant liver cancer trial

TAGS: ,

The companies had hoped to show Nexavar's effectiveness at improving hepatocellular carcinoma patients' recurrence-free survival when used after surgery or ablation had removed detectable signs of the disease. However, the trial, which enrolled more than…

Latest Report